Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak.

Higgs ES, Dubey SA, Coller BAG, Simon JK, Bollinger L, Sorenson RA, Wilson B, Nason MC, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:229-261. doi: 10.1007/82_2017_53. Review.

PMID:
28918539
2.

A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.

J Virol. 2017 May 12;91(11). pii: e00066-17. doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.

3.

A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.

Wang D, Freed DC, He X, Li F, Tang A, Cox KS, Dubey SA, Cole S, Medi MB, Liu Y, Xu J, Zhang ZQ, Finnefrock AC, Song L, Espeseth AS, Shiver JW, Casimiro DR, Fu TM.

Sci Transl Med. 2016 Oct 26;8(362):362ra145.

PMID:
27797961
4.

Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX(®) Vaccination.

Sei JJ, Cox KS, Dubey SA, Antonello JM, Krah DL, Casimiro DR, Vora KA.

Front Immunol. 2015 Oct 29;6:553. doi: 10.3389/fimmu.2015.00553. eCollection 2015.

5.

A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens.

Swaminathan G, Thoryk EA, Cox KS, Meschino S, Dubey SA, Vora KA, Celano R, Gindy M, Casimiro DR, Bett AJ.

Vaccine. 2016 Jan 2;34(1):110-9. doi: 10.1016/j.vaccine.2015.10.132. Epub 2015 Nov 10.

PMID:
26555351
6.

Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures.

Cox KS, Tang A, Chen Z, Horton MS, Yan H, Wang XM, Dubey SA, DiStefano DJ, Ettenger A, Fong RH, Doranz BJ, Casimiro DR, Vora KA.

MAbs. 2016;8(1):129-40. doi: 10.1080/19420862.2015.1109757. Epub 2015 Oct 22.

7.

Preclinical and clinical development of a dengue recombinant subunit vaccine.

Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA.

Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Review.

PMID:
26458804
8.

Internal Hernia through Paraduodenal Recess with Acute Intestinal Obstruction: A Case Report.

Husain A, Bhat S, Roy AK, Sharma V, Dubey SA, Faridi MS.

Indian J Surg. 2012 Aug;74(4):354-5. doi: 10.1007/s12262-011-0243-4. Epub 2011 May 10.

9.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, Self SG.

PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.

10.

Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.

Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR.

Cell Immunol. 2011;270(2):126-34. doi: 10.1016/j.cellimm.2011.03.027. Epub 2011 Apr 22.

PMID:
21570062
11.

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality.

Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Makadonas G, Ratcliffe SJ, Lasaro MO, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

PLoS One. 2010 Dec 22;5(12):e14385. doi: 10.1371/journal.pone.0014385.

12.

Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR.

Vaccine. 2010 Nov 23;28(50):7881-9. doi: 10.1016/j.vaccine.2010.09.079. Epub 2010 Oct 23.

PMID:
20937317
13.

Synthesis and immunological activities of novel agonists of toll-like receptor 9.

Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR.

Cell Immunol. 2010;263(1):105-13. doi: 10.1016/j.cellimm.2010.03.005. Epub 2010 Mar 10.

PMID:
20381019
14.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV.

J Infect Dis. 2010 Jan 1;201(1):132-41. doi: 10.1086/648591.

PMID:
19929694
15.

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.

Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR.

Nat Med. 2009 Aug;15(8):876-8. doi: 10.1038/nm.1989. Epub 2009 Jul 20. Erratum in: Nat Med. 2009 Nov;15(11):1333. Makedonas, George [added].

16.

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH.

Nat Med. 2009 Aug;15(8):873-5. doi: 10.1038/nm.1991. Epub 2009 Jul 20.

17.

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV; Merck V520-007/012 Study Teams.

AIDS Res Hum Retroviruses. 2009 Jan;25(1):103-14. doi: 10.1089/aid.2008.0212.

18.

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.

Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW, Robertson MN, Casimiro DR.

J Virol. 2008 Aug;82(16):8161-71. doi: 10.1128/JVI.00620-08. Epub 2008 Jun 4.

19.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.

Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.

PMID:
18433307
20.

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.

Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, Cox KS, Guan L, Long R, Persaud N, Caulfield MJ, Sadoff JC, Emini EA, Thaler S, Shiver JW.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):67-76.

PMID:
17263635
21.

A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects.

Tobery TW, Dubey SA, Anderson K, Freed DC, Cox KS, Lin J, Prokop MT, Sykes KJ, Mogg R, Mehrotra DV, Fu TM, Casimiro DR, Shiver JW.

AIDS Res Hum Retroviruses. 2006 Nov;22(11):1081-90.

PMID:
17147493
22.

Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.

Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, Schechter M, Mbewe B, Vardas E, Pitisuttithum P, Burke D, Freed D, Mogg R, Coplan PM, Condra JH, Long RS, Anderson K, Casimiro DR, Shiver JW, Straus WL.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):135-9.

PMID:
16760794
23.

Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M, Pollakis G, Paxton WA, Shiver JW, Goudsmit J.

J Virol. 2005 Sep;79(17):11247-58.

24.

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.

Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, Mbewe B, Vardas E, Schechter M, Kallas EG, Freed DC, Fu TM, Mast CT, Puthavathana P, Kublin J, Brown Collins K, Chisi J, Pendame R, Thaler SJ, Gray G, Mcintyre J, Straus WL, Condra JH, Mehrotra DV, Guess HA, Emini EA, Shiver JW.

J Infect Dis. 2005 May 1;191(9):1427-34. Epub 2005 Mar 30.

PMID:
15809900
25.

Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual.

Geels MJ, Cornelissen M, Schuitemaker H, Anderson K, Kwa D, Maas J, Dekker JT, Baan E, Zorgdrager F, van den Burg R, van Beelen M, Lukashov VV, Fu TM, Paxton WA, van der Hoek L, Dubey SA, Shiver JW, Goudsmit J.

J Virol. 2003 Dec;77(23):12430-40.

26.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011

Supplemental Content

Loading ...
Support Center